These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21109034)

  • 1. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV.
    Somogyi E; Xu J; Gudics A; Tóth J; Kovács AL; Lori F; Lisziewicz J
    Vaccine; 2011 Jan; 29(4):744-53. PubMed ID: 21109034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials.
    Coupar BE; Purcell DF; Thomson SA; Ramshaw IA; Kent SJ; Boyle DB
    Vaccine; 2006 Feb; 24(9):1378-88. PubMed ID: 16257479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins.
    Bazhan SI; Karpenko LI; Lebedev LR; Uzhachenko RV; Belavin PA; Eroshkin AM; Ilyichev AA
    Mol Immunol; 2008 Feb; 45(3):661-9. PubMed ID: 17869341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 derived peptides fused to HBsAg affect its immunogenicity.
    Gonzalez MC; Kostrzak A; Guetard D; Pniewski T; Sala M
    Virus Res; 2009 Dec; 146(1-2):107-14. PubMed ID: 19766153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.
    Egan MA; Megati S; Roopchand V; Garcia-Hand D; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Eldridge JH; Sidhu MK
    Vaccine; 2006 May; 24(21):4510-23. PubMed ID: 16140439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
    Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
    Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
    Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.
    Young KR; Smith JM; Ross TM
    Virology; 2004 Oct; 327(2):262-72. PubMed ID: 15351214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.
    Lori F
    Expert Rev Vaccines; 2011 Oct; 10(10):1371-84. PubMed ID: 21988301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies.
    Karpenko LI; Ilyichev AA; Eroshkin AM; Lebedev LR; Uzhachenko RV; Nekrasova NA; Plyasunova OA; Belavin PA; Seregin SV; Danilyuk NK; Zaitsev BN; Danilenko ED; Masycheva VI; Bazhan SI
    Vaccine; 2007 May; 25(21):4312-23. PubMed ID: 17418918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.